The raised guidance and accelerating Optune Lua/Pax adoption signal improving commercial momentum. Watch for the FDA decision on TTFields for brain metastases from NSCLC (Q4 2026) and completion of KEYNOTE D58 enrollment as the next catalysts.
Price Chart
Executive Summary
Novocure reported Q3 2026 net revenues of $193.4M (+16% YoY), above the $182.2M consensus, and a net loss of $0.09 per share, beating the consensus estimate of -$0.23. The company raised full-year 2026 revenue guidance to $736M-$743M (from $710M-$725M) and adjusted EBITDA guidance to $24M-$34M (from $0M-$15M). Optune Pax received Japanese MHLW approval for locally advanced pancreatic cancer.
Key Financial Metrics
Key Facts
- Q3 2026 net revenues of $193.4M, up 16% YoY from $167.2M
- GAAP net loss per share of $0.09, narrower than the $0.33 loss in Q3 2025
- Revenue consensus was $182.2M; EPS consensus was -$0.23
- Full-year 2026 revenue guidance raised to $736M-$743M from $710M-$725M
- Full-year 2026 adjusted EBITDA guidance raised to $24M-$34M from $0M-$15M
- Optune Pax approved by Japan's MHLW for locally advanced pancreatic cancer
- Total active patients reached 5,260, up 19% YoY
- Optune Lua active patients grew 83% YoY to 255
- Gross margin improved to 77% from 73% in Q3 2025
- Adjusted EBITDA was $15.7M, compared to -$3.0M in Q3 2025
Financial Impact
Revenue beat consensus by $11.2M (6.1%); EPS beat consensus by $0.14; guidance raised by $26M at midpoint for revenue and $24M at midpoint for adjusted EBITDA
Segment Breakdown
| Segment | Revenue |
|---|---|
| Optune Gio | Not reported |
| Optune Lua | $8.2M |
| Optune Pax | $3.7M |
Risk Factors
- Company remains unprofitable on a GAAP basis with a net loss of $10.4M in Q3
- One-time benefits of $4.4M in revenue from increased claims approval rates may not recur
- R&D expenses increased 8% YoY, driven by KEYNOTE D58 trial costs
- FDA decision on brain metastases indication is pending and uncertain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001645113-26-000081 |
| Document: nvcr-20261029.htm | 0001645113-26-000081 |
| Document: 0001645113-26-000081-index-headers.html | 0001645113-26-000081 |
| Document: 0001645113-26-000081-index.html | 0001645113-26-000081 |
| Document: 0001645113-26-000081.txt | 0001645113-26-000081 |
| 8-K Data (Synthetic) | 0001645113-26-000081 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 3d ago | 8-K | $13.11 $13.15 | ▲ +0.31% | ▲ +2.08% | $13.15 (+0.31%) |
Oct 1, 2026 4w ago | 8-K | $15.92 $14.94 | ▼ −6.16% | ▼ −6.90% | $13.15 (−17.40%) |
Sep 9, 2026 7w ago | 8-K | $15.63 $15.35 | ▼ −1.79% | ▼ −1.19% | $13.15 (−15.87%) |
Sep 1, 2026 8w ago | 8-K | $17.38 $17.83 | ▲ +2.59% | ▲ +2.15% | $13.15 (−24.34%) |
Jul 23, 2026 14w ago | 8-K | $19.99 $17.65 | ▼ −11.71% | ▼ −11.81% | $13.15 (−34.22%) |
Jun 30, 2026 17w ago | 8-K | $15.15 $15.78 | ▲ +4.16% | ▲ +4.29% | $13.15 (−13.20%) |
Jun 18, 2026 19w ago | 8-K | $14.28 $13.61 | ▲ +4.69% | ▲ +4.38% | $13.15 (+7.91%) |
Jun 5, 2026 21w ago | 8-K | $16.85 $17.24 | ▲ +2.31% | ▲ +2.61% | $13.15 (−21.96%) |
Jun 3, 2026 21w ago | Insider Cluster | $17.99 $17.16 | ▼ −4.61% | ▼ −2.04% | $13.15 (−26.90%) |
Jun 3, 2026 21w ago | Insider Cluster | $17.99 $17.16 | ▼ −4.61% | ▼ −2.02% | $13.15 (−26.90%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers